Source Paper
Safety and antitumor activity of recombinant soluble Apo2 ligand
Avi Ashkenazi, Roger C. Pai, Sharon Fong, Susan Leung, David A. Lawrence et al.
Journal of Clinical Investigation • 1999
Tumor Xenograft Prevention Study
Objective: To assess the ability of Apo2L (Apo2 ligand/TRAIL) treatment to reduce tumor incidence when administered shortly after tumor xenograft injection in athymic mice
Gather these items before starting the experiment. Check off items as you prepare.
As an Amazon Associate, we earn from qualifying purchases. Product links help support this free resource.
Protocol Steps
Tumor xenograft injection
Inject tumor cells into athymic mice to establish xenograft tumors
Note: Timing of injection is critical as Apo2L treatment follows shortly after
View evidence from paper
“Treatment of athymic mice with Apo2L shortly after tumor xenograft injection markedly reduced tumor incidence”
Apo2L treatment initiation
Administer Apo2L treatment shortly after tumor xenograft injection
Note: Treatment timing is critical for tumor incidence reduction
View evidence from paper
“Treatment of athymic mice with Apo2L shortly after tumor xenograft injection markedly reduced tumor incidence”
Monitor tumor development
Assess tumor incidence and progression in treated mice
Note: Measure tumor incidence as primary outcome
View evidence from paper
“Treatment of athymic mice with Apo2L shortly after tumor xenograft injection markedly reduced tumor incidence”
Assess tumor cell apoptosis and progression
Evaluate tumor cell apoptosis induction, tumor progression suppression, and survival improvement
Note: Multiple outcome measures assessed
View evidence from paper
“Apo2L treatment of mice bearing solid tumors induced tumor cell apoptosis, suppressed tumor progression, and improved survival”
Optional combination therapy
In some mice, combine Apo2L treatment with chemotherapeutic drugs 5-fluorouracil or CPT-11
Note: Combination therapy showed synergistic effects
View evidence from paper
“Apo2L cooperated synergistically with the chemotherapeutic drugs 5-fluorouracil or CPT-11, causing substantial tumor regression or complete tumor ablation”